Orion’s ODM-212 Trial for Solid Tumours Starts Phase 1b/2
Orion has opened enrollment for TEADCO, a multicenter, open-label Phase 1b/2 basket trial testing its oral pan-TEAD inhibitor ODM-212...
eClinical Tech News
Phase I Trial of PST-611 for Dry AMD Completes Last Visit
PulseSight has completed follow-up on all six patients in its first-in-human PST-611 study for geographic atrophy secondary to dry...
A New Hope: NP137’s Surging Results in Pancreatic Cancer
Phase 1b data from LAPNET-01 in locally advanced pancreatic ductal adenocarcinoma reported median progression-free survival of 10.85 months, median...
LB-102 Phase 2 Schizophrenia Trial Results in JAMA Psych
In a four-week, placebo-controlled Phase 2 study in acute schizophrenia, LB-102 achieved statistically significant improvement versus placebo at all...
Maze Therapeutics Reveals Tremendous $150 Million Offering
Maze Therapeutics priced a $150 million underwritten public offering, selling 5.54 million shares at $23.50 and issuing pre-funded warrants...
ASCO 2026 Spotlight: ProstAct Phase 3 Late-Breaking Data
Preliminary safety and dosimetry results from the 36-patient lead-in of Telix’s Phase 3 ProstACT Global study will be delivered...
Zymeworks Presents New Phase 1 Data for ZW191 ADC at AACR
ZW191 delivered a confirmed objective response rate of 61% at 6.4–9.6 mg/kg in platinum‑resistant ovarian cancer, with a 57%...
Miv-cel Shows Durable, Significant Benefit for Stiff Person
In a single-arm registrational Phase 2 trial (KYSA-8) in 26 patients with stiff person syndrome (SPS), a one-time infusion...
Powerful GABAB PAM Candidate Halts Primate Chronic Cough
In a non-human primate chronic cough model, Addex’s orally available GABAB positive allosteric modulator cut citric acid–induced cough frequency...
Genetic Data Offers Breakthrough Hope for Pancreatic Cancer
ctDNA from 123 atebimetinib-treated patients showed rare emergent MAPK pathway alterations and minimal early molecular evolution, with resistance patterns...